// App-Quantinova.ai

: Extended follow-up results from the CheckMate 274 trial.

Researchers

Presenter

  • Matt D. Galsky

Principal Investigators

  • Alfred Alfred Witjes

  • Jürgen E. Gschwend

  • Michael Schenker

  • Begoña Pérez Valderrama

  • Yoshihiko Tomita

  • Aristotelis Bamias

  • Thierry Lebret

  • Shahrokh F. Shariat

  • Se Hoon Park

  • Mads Agerbaek

  • Gautam Gopalji Jha

  • Frank Stenner

  • Santanu Dutta

  • Federico Nasroulah

  • Joshua Zhang

  • Lynne Brophy

  • Dean F. Bajorin

Medical Centers

  • Hôpital Foch, Paris-Saclay University UVSQ, Versailles, France

  • National and Kapodistrian University of Athens, Athens, Greece

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Technical University of Munich, University Hospital Rechts der Isar, Munich, Germany

  • Medical University Vienna - General Hospital, Vienna, Austria

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University Hospital Basel, Basel, Switzerland

  • Mhealth Fairview Clinics and Surgery Center, Minneapolis, MN

  • Sf Nectarie Oncology Center Craiova, Craiova, Romania

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Nigata University Graduate School of Medical and Dental Sciences, Japan

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Radboud University, Nijmegen, Netherlands

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Aarhus University Hospital, Aarhus, Denmark

Locations

  • Germany

  • Netherlands

  • Republic of South Korea

  • Denmark

  • France

  • Japan

  • Austria

  • Spain

  • Switzerland

  • Greece

  • Romania

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02632409

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved